Abstract
Background Estimating attributable risk (AR) through self-controlled case series (SCCS) analyses alone may limit generalizability because SCCS only incorporate vaccinated patients with the outcome (e.g., Guillain-Barré syndrome [GBS]) who may differ from the overall population recommended for vaccination.
Objective We aimed to demonstrate background event incidence rates’ impact on vaccine-specific GBS ARs and to standardize ARs across different vaccine studies by applying a generalizable, population-based GBS background rate for improved comparability and to better estimate the expected population-level ARs.
Methods We identified post-licensure SCCS vaccine studies and GBS background rates using US Medicare data via targeted literature review. GBS control period rates from SCCS vaccine studies were extracted or calculated. Population-level ARs were calculated for each vaccine using published background GBS rates and the original SCCS-generated incidence rate ratios (IRRs).
Results Published vaccine-specific GBS IRRs ranged from 2.02 (95%CI: 0.93–4.40) for RSVPreF to 4.96 (95%CI: 1.43–17.27) for recombinant zoster vaccine (RZV). Study-specific ARs per 100,000 doses ranged from 0.28 (H1N1) to 0.90 (RSVPreF). Vaccines with lower control period GBS rates had a lower attributable risk for a given IRR. After standardization using published background GBS rates, population-level ARs were higher for vaccines with higher IRRs. For example, when using the H1N1 vaccine control period rate as the GBS background rate for AR calculation, RSVPreF had the lowest AR per 100,000 doses (0.21) and RZV the highest (2.37).
Conclusion AR calculation is dependent on the control period rate within a given SCCS analysis. ARs derived exclusively from SCCS analyses may lead to incorrect conclusions regarding an adverse event’s absolute risk if included in product labels due to a lack of external validity. Using a representative background rate from the recommended vaccinee population, along with SCCS-derived IRR, to calculate the expected population-level AR may offer more accurate vaccine risk-benefit assessments.
Competing Interest Statement
CL, ELC, JW, SPK, QL, KLD, MML, BDG and EB are employees of Pfizer and may hold stock or stock options. JAL has received research grants, honoraria, and speaker fees from Pfizer Inc. for related/unrelated work; research grants and honoraria from Merck, Sharp, & Dohme for unrelated work; honoraria from Valneva for unrelated work; consulting fees from Seqirus Inc. for unrelated work; and honoraria from VaxCyte for unrelated work.
Funding Statement
This study was funded by Pfizer Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- CI
- confidence interval;
- FFS
- fee-for-service;
- GBS
- Guillain-Barré syndrome;
- IRR
- incidence rate ratio;
- PY
- person-years;
- RSV
- respiratory syncytial virus;
- RSVpreF
- bivalent (RSV A and B) stabilized prefusion F protein subunit vaccine;
- RSVpreF3
- the adjuvanted RSV prefusion F protein-based vaccine;
- RZV
- recombinant zoster vaccine;
- SCCS
- self-controlled case series.
